𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Trials And Tribulations: Thoughts On The Organisation Of Multicentre Clinical Studies: Cancer Research Campaign Working Party

Book ID
125716363
Publisher
BMJ Publishing Group
Year
1980
Tongue
English
Weight
796 KB
Volume
281
Category
Article
ISSN
0959-8138

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Commentary on β€œInternational phase III t
Commentary on β€œInternational phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: Long-term results of the BA06 30894 trial.” Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK, and the International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; Australian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; Finnbladder; Norwegian Bladder Cancer Study Group; Club Urologico Espanol de Tratamiento Oncologico Group. Medical Research Council Clinical Trials Unit, London, United Kingdom: J Clin Oncol 2011;29:2171–7
✍ H. Barton Grossman πŸ“‚ Article πŸ“… 2012 πŸ› Elsevier Science 🌐 English βš– 89 KB
Can multiparametric magnetic resonance i
Can multiparametric magnetic resonance imaging predict upgrading of transrectal ultrasound biopsy results at more definitive histology?11Mohamed Abd-Alazeez receives funding from the Egyptian government. Mark Emberton and Hashim U. Ahmed receive funding from USHIFU and Advanced Medical Diagnostics for clinical trials. Mark Emberton is a paid consultant for Steba Biotech, USHIFU and Sanofi-Aventis. Mark Emberton has received research support by GSK for a study evaluating the role of MRI in men with prostate cancer. Mark Emberton and Hashim Ahmed have previously received medical consultancy fees from GE Healthcare/Oncura and Hashim Ahmed previously from Steba Biotech. Mark Emberton is a medical director of Mediwatch PLC. Hashim Uddin Ahmed and Mark Emberton receive funding from the Medical Research Council, the NIHR-HTA, NIHR-i4i, the US NIH/NCI, Pelican Cancer Foundation, Prostate Cancer UK, and St PeterΧ³s Trust. This work was part funded by research support for Mark Emberton and Alex Kirkham from the UK National Institute of Health Research UCLH/UCL Comprehensive Biomedical Research Centre, London, UK.
✍ Abd-Alazeez, Mohamed; Ahmed, Hashim U.; Arya, Manit; Allen, Clare; Dikaios, Niko πŸ“‚ Article πŸ“… 2014 πŸ› Elsevier Science 🌐 English βš– 415 KB